NSABP B-49

Closed to Accrual

Return to Protocol Table

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Principal Investigator

Patrick Flynn, MD

Status

Closed to Accrual

Date Opened To Accrual

April 04 2012

Date Closed to Accrual

November 21 2013

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To determine if the TC regimen is non-inferior to the anthracycline-based chemotherapy regimens in terms of invasive disease-free survival (IDFS) by combining B-49 data with the TAC and TC arms of NSABP B-46-I/USOR 07132 and the data from USOR 06-090.

Patient Population

Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Target Accrual

1843

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.